Rex Capital Advisors’s AbbVie ABBV Stock Holding History

Rex Capital Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-8,149	Closed	-$460K	–	58
2014 Q2	$460K	Hold	8,149	–	–	0.41%	20
2014 Q1	$419K	Hold	8,149	–	–	0.42%	21
2013 Q4	$430K	Hold	8,149	–	–	0.47%	22
2013 Q3	$365K	Hold	8,149	–	–	0.4%	26
2013 Q2	$337K	Buy	+8,149	New	+$356K	0.27%	26

Other funds holding ABBV

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Rex Capital Advisors's ABBV Position: Q3 2014 in Review

Rex Capital Advisors sold out of AbbVie (ABBV) in Q3 2014, closing a stake of 8,149 shares — an estimated $460K sold.

Rex Capital Advisors first reported a position in ABBV in Q2 2013 and held it in 5 quarters. The position peaked at $460K in Q2 2014. 1,503 funds tracked by Wall St. Rank hold ABBV as of Q3 2014.

Rex Capital Advisors reported no remaining AbbVie position as of Q3 2014 after selling out during the quarter.
Rex Capital Advisors sold 8,149 AbbVie shares in Q3 2014, an estimated $460K.
Rex Capital Advisors first reported a position in AbbVie in Q2 2013 and held it in 5 quarters.
Rex Capital Advisors's AbbVie position peaked at $460K in Q2 2014.
1,503 funds tracked by Wall St. Rank held AbbVie as of Q3 2014.

Based on Rex Capital Advisors's 13F filing for Q3 2014, filed 14 Nov 2014.